Editas Medicine

Ticker EDIT

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

51-200 Employees
Based in Cambridge, Massachusetts

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic…More

Visit website

REPORT RATINGS

4.7 / 5.0 (134)

Editas Medicine reports have an aggregate usefulness score of 4.7 based on 134 reviews.

Editas Medicine